How This Evidence Evolved
Alzheimer's Disease-Modifying Therapy
The amyloid hypothesis tested
Timeline
Early observations and pilot data that first suggested a new direction
Landmark RCTs and pivotal trials that established the evidence base
For lecanemab, obtain a screening MRI within 12 months of initiation and use MRI to monitor ARIA. APOE4 carriers, especially homozygotes, have higher ARIA risk; recommend genotyping to inform risk discussions.
CDR-SB at week 78: EMERGE difference -0.39 (P=.012); ENGAGE 0.03 (P=.833).
CDR-SB change at 18 months: lecanemab 1.21 vs placebo 1.66 (difference −0.45; P<.001)
iADRS at 76 weeks, low/medium tau: donanemab -6.02 vs placebo -9.27 (P<.001).
Integration into clinical practice guidelines and recommendations
Lecanemab for early AD with confirmed amyloid; screening MRI and ARIA monitoring required.
Current standard of care and ongoing research directions
Landmark Trials in This Story
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.
CDR-SB at week 78: EMERGE difference -0.39 (P=.012); ENGAGE 0.03 (P=.833).
Lecanemab in Early Alzheimer's Disease
CDR-SB change at 18 months: lecanemab 1.21 vs placebo 1.66 (difference −0.45; P<.001)
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial
iADRS at 76 weeks, low/medium tau: donanemab -6.02 vs placebo -9.27 (P<.001).
Treatment of Alzheimer Disease.
Review: lecanemab full FDA approval and limited Medicare coverage in July 2023; donanemab similar approval in July 2024.
Explore the evidence yourself
Ask AttendMe about any trial, guideline, or clinical question. Evidence-ranked answers from 3.7M+ peer-reviewed articles.